PLRX
HEALTHCAREPliant Therapeutics Inc
$1.23+0.02 (+1.65%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PLRX Today?
No stock-specific AI insight has been generated for PLRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.09$1.95
$1.23
Fundamentals
Market Cap$76M
P/E Ratio—
EPS$-2.43
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume562K
Avg Volume (10D)—
Shares Outstanding61.9M
PLRX News
20 articles- Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceYahoo Finance·May 6, 2026
- Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsYahoo Finance·Apr 30, 2026
- Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual MeetingGlobeNewswire Inc.·Apr 18, 2026
- Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual MeetingYahoo Finance·Mar 18, 2026
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial ResultsYahoo Finance·Mar 11, 2026
- Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer ConferenceMarketbeat·Mar 1, 2026
- Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science ConferenceYahoo Finance·Feb 23, 2026
- Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of DirectorsYahoo Finance·Jan 9, 2026
- Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid TumorsYahoo Finance·Dec 4, 2025
- Pliant Therapeutics to Participate in the Piper Sandler Healthcare ConferenceYahoo Finance·Dec 1, 2025
- Idiopathic Pulmonary Fibrosis Research Report 2025-2035: Market Led by Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore as Next-Gen Antifibrotics and Targeted Therapies Drive InnovationYahoo Finance·Nov 18, 2025
- Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 6, 2025
- 3 Promising Penny Stocks With Market Caps Under $500MYahoo Finance·Oct 17, 2025
- Align downgraded, NetEase upgraded: Wall Street's top analyst callsYahoo Finance·Oct 10, 2025
- Penny Stocks To Watch With Market Caps Under $700MYahoo Finance·Sep 8, 2025
- Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 7, 2025
- 3 Promising Penny Stocks With Market Caps Under $200MYahoo Finance·Jul 15, 2025
- Pliant halts bexotegrast development for IPF after trial resultsClinicaltrialsarena·Jun 30, 2025
- Pliant Therapeutics Provides Update on BEACON-IPFYahoo Finance·Jun 27, 2025
- Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceYahoo Finance·May 21, 2025
All 20 articles loaded
Price Data
Open$1.22
Previous Close$1.21
Day High$1.23
Day Low$1.19
52 Week High$1.95
52 Week Low$1.09
52-Week Range
$1.09$1.95
$1.23
Fundamentals
Market Cap$76M
P/E Ratio—
EPS$-2.43
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume562K
Avg Volume (10D)—
Shares Outstanding61.9M
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—